12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Infliximab regulatory update

EMA's CHMP issued a positive opinion recommending approval of duplicate MAAs from Celltrion and partner Hospira for Inflectra/Remsima infliximab (CT-P13), a biosimilar of Remicade infliximab. Hospira plans to launch the biosimilar as Inflectra in Eastern and Central Europe by year end and said prices for the biosimilar have not been determined....

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >